FindTrial
Sign In

Hormonal Therapy for hypogonadism

A RANDOMIZED STUDY COMPARING VARIOUS REGIMENS OF GONADOTROPIN THERAPY FOR MALE HYPOGONADOTROPIC HYPOGONADISM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017819
Enrollment
30
Registered
2019-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E230- Hypopituitarism

Interventions

Intervention1: FSH Priming prior to combination gonadotropin: FSH (Follicle Stimulating Hormone) priming (ink FSH 150 IU thrice a week ) for 3 months followed by addition of hCG (human chorionic gonad

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Congenital or acquired prepubertal hypogonadotropic hypogonadism 2. Azoospermia 3. Affordability for gonadotrophin therapy

Exclusion criteria

Exclusion criteria: 1. Age less than 14 years 2. Age more than 40 years 3. Postpubertal or adult onset hypogonadotrophic hypogonadism 4. Functional hypogonadism (eating disorder or chronic disease) 5. Testicular disorders (primary hypogonadism) 6. Cryptorchidism 7. Deranged liver functions

Design outcomes

Primary

MeasureTime frame
Induction of spermatogenesisTimepoint: 3 months, 6 months, 9 months, 12 months—

Secondary

MeasureTime frame
Improvement in hormonal profileTimepoint: 3, 6, 9, 12 months;Testicular volumeTimepoint: 3 months, 6 months, 9 months, 12 months—

Countries

India

Contacts

Public ContactRama Walia

Postgraduate Institute of Medical Education and ResearchSector 12

ramawalia@rediffmail.com9872997438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026